Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITALIZE: Riliprubart vs IVIg in CIDP
NCT06290141Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Aug 2024
- Primary completion
- Jul 2027
- Modality
- IgG Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Sanofi. Started Aug 2024; status: recruiting.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT06290141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290141.